Neurotrophins and depression
by
Altar CA
Mayland Research Laboratories,
Otsuka America Pharmaceutical,
Rockville 20850, USA.
Trends Pharmacol Sci 1999 Feb; 20(2):59-61


ABSTRACT

Exogenous delivery of the neurotrophic factors, brain-derived neurotrophic factor (BDNF) or neurotrophin-3 (NT-3), promotes the function, sprouting and regrowth of 5-HT-containing neurones in the brains of adult rats. Similar infusions of BDNF into the dorsal raphe nucleus produce an antidepressant effect, as evaluated by several 'learned helplessness' paradigms. Environmental stressors such as immobilization induce depression and decrease BDNF mRNA. Antidepressants increase BDNF mRNA in the brain, via 5-HT2A and beta-adrenoceptor subtypes and prevent the stress-induced decreases in BDNF mRNA. In this article, Tony Altar discusses how existing treatments of depression might work by increasing endogenous brain levels of BDNF or NT-3, which in turn could promote monoamine-containing neurone growth and function. Drugs that selectively stimulate the production of neurotrophins could represent a new generation of antidepressants.

CRF
NMDA
SSRIs
NARIs
RIMAs
1990s
Options
Ketamine
Antisense
SSRIs/SNRIs
Comparisons
Neurotrophin 3
New anxiolytics
Antidepressants
Vagus stimulation
New antidepressants
Neurokinins/substance P
Nootropics ('smart drugs')
SNaRIs, NaSSAs, and NaRIs
Neurotrophins and antidepressants
Antidepressants and new brain cells
The neurotrophic effects of antidepressants

Refs
and further reading

HOME
HedWeb
Nootropics
Cocaine.org
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family